HONG KONG, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Cellyan Biotechnology Co., Ltd (Nasdaq: HKPD) (the "Company"), a leading provider of over the counter (“OTC”) pharmaceutical cross-border e-commerce supply chain services in Hong Kong, today announced that it received a notification letter (the “Notification Letter”) dated January 12, 2026 from Nasdaq's Listing Qualifications Department indicating that the closing bid price of the Company's class A ordinary shares of par value of US$0.001 each was below the minim ...

Core Viewpoint - Hong Kong Pharma Digital Technology Holdings Limited (HKPD) successfully passed all proposals at its 2025 annual meeting, indicating a strategic shift and governance updates for the company [1][2][3]. Group 1: Shareholder Proposals - Proposal No. 1 involved the re-election of five directors to serve until the 2026 Annual Meeting [1]. - Proposal No. 2 ratified the appointment of Onestop Assurance PAC as the independent registered public accounting firm for the fiscal year ending March 31, 2026 [1]. - Proposal No. 3 increased the authorized share capital from US$100,000 to US$1,000,000, allowing for a total of 1,000,000,000 ordinary shares [1]. Group 2: Share Structure Changes - Proposal No. 4 re-designated and re-classified the company's shares into Class A and Class B ordinary shares [2]. - Proposal No. 5 approved a Reverse Share Split and Share Consolidation of the company's issued and outstanding ordinary shares [2]. Group 3: Corporate Identity and Governance - Proposal No. 6 changed the company's name to "Cellyan Biotechnology Co., Ltd" and its foreign name to "生研生物公司" [3]. - Proposal No. 7 adopted the fourth amended and restated memorandum and articles of association [3]. - Proposal No. 8 involved the repurchase of 7,150,000 Class A Ordinary Shares and the issuance of Class B Ordinary Shares [3]. - Proposal No. 9 approved the 2025 Equity Incentive Plan [3]. Group 4: Company Overview - HKPD specializes in OTC pharmaceutical cross-border e-commerce supply chain services through its subsidiary, Joint Cross Border Logistics Company Limited [4]. - The company also engages in OTC pharmaceutical cross-border procurement and distribution via its subsidiary, V-Alliance Technology Supplies Limited [4]. - Joint Cross Border provides a comprehensive service offering, including product procurement, logistics, and delivery for Mainland Chinese customers seeking OTC pharmaceutical products [5][6].

Group 1 - The top five gainers among Chinese concept stocks include: Hong Kong Pharmaceutical Digital Technology up 47.41%, Smart Logistics up 28.61%, Lixiang Education up 24.6%, Chengdao Environmental Technology up 19.76%, and Mercurity Fintech up 15.37% [1][1][1] Group 2 - Hong Kong Pharmaceutical Digital Technology (HKPD) closed at 1.710 with a gain of 47.41%, increasing by 0.550 and a trading volume of 2.5604 million [1][1][1] - Smart Logistics (SLGB) closed at 5.260 with a gain of 28.61%, increasing by 1.170 and a trading volume of 4.1425 million [1][1][1] - Lixiang Education (LXEH) closed at 0.5622 with a gain of 24.60%, increasing by 0.1110 and a trading volume of 12.1477 million [1][1][1] - Chengdao Environmental Technology (CDTG) closed at 0.7200 with a gain of 19.76%, increasing by 0.1188 and a trading volume of 0.0341 million [1][1][1] - Mercurity Fintech (MFH) closed at 11.260 with a gain of 15.37%, increasing by 1.500 and a trading volume of 1.8935 million [1][1][1]

Group 1 - The top five Chinese concept stocks that experienced the largest declines at closing were: 707 Cayman Holdings down 65.81%, MoBe down 33.33%, Deep Fan Lian down 23.78%, Zhengye Biology down 23.02%, and Hongyao Digital Technology down 22.76% [1][1][1] Group 2 - 707 Cayman Holdings had a latest price of 0.759 with a decline of 1.461 and a trading volume of 29.17 million [1][1][1] - MoBe's latest price was 0.0002, down by 0.0001 with a trading volume of 0.00024 million [1][1][1] - Deep Fan Lian's latest price was 0.3026, down by 0.0944 with a trading volume of 0.1519 million [1][1][1] - Zhengye Biology's latest price was 9.750, down by 2.915 with a trading volume of 4.3126 million [1][1][1] - Hongyao Digital Technology's latest price was 1.120, down by 0.330 with a trading volume of 1.3085 million [1][1][1]

Group 1 - The top five gainers among Chinese concept stocks include: Hong Kong Pharmaceutical Digital Technology up 35.24%, Oriental Culture up 33.22%, Rich Sparkle Holdings up 26.81%, Xiao I Robot up 22.3%, and Huibao Holdings up 21.62% [1][1][1] - Hong Kong Pharmaceutical Digital Technology (HKPD) closed at 1.420 with a gain of 0.370 and a trading volume of 297 million [1][1][1] - Oriental Culture (OCG) closed at 3.850 with a gain of 0.960 and a trading volume of 3.8226 million [1][1][1] - Rich Sparkle Holdings (ANPA) closed at 52.880 with a gain of 11.180 and a trading volume of 1.2434 million [1][1][1] - Xiao I Robot (AIXI) closed at 1.810 with a gain of 0.330 and a trading volume of 1.4992 million [1][1][1] - Huibao Holdings (FEBO) closed at 0.9000 with a gain of 0.1600 and a trading volume of 862.84 thousand [1][1][1]

Competitive Landscape - The company operates in a highly competitive supply chain services industry, facing challenges from large logistics providers potentially expanding into OTC pharmaceutical services [49]. - The company may face increased competition from e-commerce platforms developing their own logistics networks, impacting market share [53]. - The company relies heavily on the e-commerce industry, with a significant portion of orders generated from merchants selling imported OTC pharmaceutical products [61]. - The company ranked first in the OTC pharmaceutical cross-border e-commerce market in Mainland China by revenue in 2022, according to the F&S Report [209]. - The company has established itself as a leading provider of third-party supply chain services in the OTC pharmaceutical market in Mainland China [209]. Customer Dependency - Significant customers contributed a notable percentage of total revenue, and losing any of them could adversely impact financial performance [43]. - In the fiscal year ended March 31, 2024, four customers accounted for over 5% of total revenues, contributing 15.5%, 12.0%, 6.1%, and 5.9% respectively [56]. - For the fiscal year ended March 31, 2025, six customers accounted for over 5% of total revenues, contributing 11.36%, 7.87%, 7.45%, 6.39%, 5.69%, and 5.29% respectively [56]. - One significant customer, CaiNiao, contributed approximately 15.5% and 7.45% of total revenues for fiscal years 2024 and 2025 respectively [57]. Financial Risks - The company has not historically declared or paid dividends, making returns dependent on share price appreciation [47]. - The market price of the company's Ordinary Shares has been volatile, with past dips under $1 raising delisting risks under Nasdaq rules [47]. - The company relies on dividends from its Hong Kong subsidiaries for cash flow, and any restrictions on these payments could adversely affect operations [46]. - Capital requirements for expansion plans may differ from expectations, potentially impacting financial condition if financing is not secured [68]. - The company has incurred significant debt, including a long-term loan of HK$6,956,400 (approximately US$888,895) from the Bank of China (Hong Kong) in August 2023, with a variable interest rate [95]. Regulatory and Compliance Risks - The company’s operations are significantly affected by the evolving legal and regulatory environment in Hong Kong and China, which may impose additional risks [48]. - Compliance with complex regulations is essential, and failure to do so could result in significant penalties and reputational harm [80]. - The company is subject to various laws and regulations in Hong Kong, including the Import and Export Ordinance and the Pharmacy and Poisons Ordinance, which govern its operations [81]. - The PRC government has initiated regulatory actions that may impact business operations, including increased oversight of companies listed overseas and cybersecurity reviews [119]. - The enactment of the Hong Kong National Security Law could materially affect the operations of Hong Kong subsidiaries [122]. Supply Chain and Inventory Management - The company is exposed to risks associated with OTC pharmaceutical inventories, including quality issues and logistics-related incidents [44]. - The company must manage inventory effectively to meet customer demand, as misjudgment could lead to revenue decline [67]. - Supplier relationships are critical, and disruptions such as production issues or bankruptcies could hinder the company's ability to procure necessary products in a timely manner [75]. - The company relies on independent third parties for logistics services, which are subject to risks including labor disputes and regulatory changes that could impact service availability and costs [76]. - Supply contracts with suppliers typically last six months to one year, and any termination or modification could adversely affect the company's supply chain and financial condition [77]. Market Conditions - The company’s growth is significantly influenced by international commerce and e-commerce trends, as well as macroeconomic factors affecting demand for OTC pharmaceutical products [44]. - Economic downturns may lead to decreased demand for cross-border OTC pharmaceutical products, adversely affecting the company's supply chain services [63]. - The market for the company's products and services may be adversely affected by prolonged economic slowdowns in Hong Kong and China [126]. - The anticipated negative impacts of executive or legislative actions could adversely affect the market price of the Ordinary Shares, regardless of actual operating performance [142]. Operational Challenges - Disruptions to warehousing and logistics facilities could materially affect business operations and financial results [72]. - The company’s ability to deliver products may be impacted by disruptions in the supply chain due to natural disasters or health crises [188]. - The company is exposed to risks associated with doing business in Hong Kong, including potential government intervention that could impact operations and share value [117]. Strategic Initiatives - The company aims to expand its sales channels and pursue growth opportunities beyond consignment sales [224]. - The company has established partnerships with major logistics platforms like CaiNiao, which helps reduce overall operating costs through increased order volumes [227]. - The proprietary ERP system "Extraordinary Supply Chain V2.0" enhances operational efficiency by optimizing workflows and reducing logistics fulfillment costs [226]. Shareholder Considerations - The Chief Executive Officer and Chairman, Mr. Lap Sun Wong, holds approximately 56.77% of the voting power of the company's outstanding share capital, potentially limiting shareholder influence [162]. - Shareholders have limited rights under Cayman Islands law to convene general meetings or present proposals, which may affect their ability to influence corporate governance [175][176]. - The company's memorandum and articles of association contain anti-takeover provisions that could limit shareholders' opportunities to sell shares at a premium [182]. Future Outlook - The company plans to file an annual report on Form 20-F within four months of the end of each fiscal year, but the information provided will be less extensive and timely compared to U.S. domestic issuers [170]. - The company is classified as an "emerging growth company" and will take advantage of reporting exemptions until it no longer qualifies, which could be when total annual gross revenue exceeds $1.235 billion or the market value of Ordinary Shares held by non-affiliates exceeds $700 million [166].

As filed with the United States Securities and Exchange Commission on December 10, 2024. Registration No. 333-282876 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO. 3 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 HONG KONG PHARMA DIGITAL TECHNOLOGY HOLDINGS LIMITED (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant's Name into English) Cayman Islands 5122 Not Applicable (State or other jurisdiction of i ...

As filed with the United States Securities and Exchange Commission on November 27, 2024. Registration No. 333-282876 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO. 2 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 HONG KONG PHARMA DIGITAL TECHNOLOGY HOLDINGS LIMITED Room B1, 5/F., Well Town Industrial Building, 13 Ko Fai Road, Yau Tong, Kowloon Hong Kong +852 2618-9289 (Address, including zip code, and telephone number, including area code, of Regis ...

As filed with the United States Securities and Exchange Commission on November 20, 2024. Registration No. 333-282876 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO. 1 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 HONG KONG PHARMA DIGITAL TECHNOLOGY HOLDINGS LIMITED (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant's Name into English) Cayman Islands 5122 Not Applicable (Names, address, including zip co ...

As filed with the United States Securities and Exchange Commission on October 29, 2024. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 HONG KONG PHARMA DIGITAL TECHNOLOGY HOLDINGS LIMITED (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant's Name into English) Cayman Islands 5122 Not Applicable (State or other jurisdiction of incorporation or organizati ...